ERBB2 and gastric cancer: In consideration of the MyPathway study, we designed a histology-independent phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in Japanese patients with cancer types other than breast and gastric cancers harboring HER2 amplification.